Latest news for Arcandor (OTC:ACAGF) Stock

Arcandor AG is in insolvency. Arcandor was a German handels and tourism company, with the divisions Karstadt, mail-order operation (Primondo) and Thomas Cook.

Arcandor AG

News

Events

Trading Ideas

PLTR

Live On CNBC, Palantir CEO Alex Karp Discuss Palantir's AI Platform Conference

Goldman Sachs analyst Kate McShane maintains Petco Health and Wellness (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>) with a Buy and lowers the price target from $5 to $4.

Price Target

Analyst Ratings

WOOF

Goldman Sachs Maintains Buy on Petco Health and Wellness, Lowers Price Target to $4

Leafly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFLY#NASDAQ">LFLY</a>) announced Thursday that it's expanding its support of the legal New York cannabis market via a new partnership with the New York Cannabis Retail Association (NYCRA), a non-profit coalition of New York dispensary owners united under the slogan &#8220;Collaboration Over Competition.&#8221;
The new collaboration, notes Leafly, seeks aims to help create a more sustainable, equitable and inclusive cannabis industry.
Why It Matters: Leafly and NYCRA agreed to sponsor a series of industry events in 2024 and also to work on implementing marketing initiatives to strengthen New Yorkers&#8217; awareness of the importance of buying legal and local cannabis.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12110611/ccc-oct-24-banner__1_-1-5.gif" alt="" class="wp-image-545021" /></a></figure>
"The operating environment in the Empire State for legal cannabis retailers has been formidable and the continued proliferation of unlicensed retailers in New York creates unfair competition for licensed retailers and confusion for cannabis consumers," Leafly CEO Yoko Miyashita said.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/22/11/28589207/a-dictionary-of-weed-slang-leaflys-leafy-lexicon">A Dictionary Of Weed Slang: Leafly&#8217;s Leafy Lexicon</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
The new partnership follows years of attempts by New York officials and law enforcement to tackle the growing issue of the illegal cannabis market. That said, New York Governor Kathy Hochul, NYC Mayor Eric Adams and other key city officials recently <a href="https://www.governor.ny.gov/news/governor-hochul-and-mayor-adams-announce-more-1000-illegal-cannabis-shops-have-been-shut-down">announced</a> that more than 1,000 illicit cannabis stores have been shut down <a href="https://www.benzinga.com/markets/cannabis/22/11/28589207/a-dictionary-of-weed-slang-leaflys-leafy-lexicon">across NY</a>, including 779 illegal stores padlocked in New York City and an additional 230 closures statewide.
Enter the latest effort by Leafly and NYCRA.
"As the first cannabis marketplace to operate in New York, we have seen first-hand the struggles legal cannabis businesses face in a challenging regulatory environment and unfair competition from thousands of unlicensed operators who sell unregulated cannabis to New Yorkers and tourists alike," Miyashita explained. "Simply put, retailers deserve to operate in a fair and competitive marketplace and the citizens of New York deserve access to safe products and information to make informed purchasing decisions."
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/39777553/is-the-worst-over-for-new-yorks-beleaguered-weed-market-sales-projections-optimistic-though-cann">Is The Worst Over For New York&#8217;s Beleaguered Weed Market? Sales Projections Optimistic Though Cannabis Recall Debacle Hits Home</a></li>
</ul>

Cannabis

Regulations

Entrepreneurship

Politics

LFLY

New Partnership Targets Unlicensed Cannabis Shops In New York, Here's How

DirecTV Reports Subscriber Losses Due To Disney Licensing Dispute, According To Remarks At Goldman Sachs Conference

Sanara MedTech Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smti#NASDAQ">SMTI</a>), along with InfuSystem Inc., recently entered into an exclusive U.S. distribution agreement with ChemoMouthpiece, LLC. Sanara will execute the terms of the agreement with the help of SI Healthcare Technologies (SI Technologies), which is a 50/50 joint venture between SMTI and InfuSystem.
ChemoMouthpiece owns and manufactures a clinically validated product named Chemo Mouthpiece &mdash; an oral cryotherapy device that brings relief to oral mucositis-affected patients. This device perfectly aligns with Sanara&#39;s skincare strategy. The company further aims to provide the device to oncology patients undergoing chemotherapy.
Following the announcement, shares of Sanara rose 0.5% to $33.51 yesterday. With the company gaining a high level of synergies from its collaborations within the skincare market, we expect market sentiment to remain positive around this development.
<h2>About Sanara&#39;s Distribution Agreement With ChemoMouthpiece</h2>
Under the agreement, SI Technologies will be the exclusive distributor of ChemoMouthpiece&#39;s kits in the United States. SI Technologies plans to market and distribute the product to approximately 3,000 cancer centers through InfuSystem&#39;s existing sales team. It will purchase&nbsp;the product kits from ChemoMouthpiece at a fixed price and pay a royalty on net revenues for the use of the product&#39;s intellectual property.
For investors&#39; note, the Chemo Mouthpiece is FDA 501(k) approved.
<h2>Financial Details</h2>
Sanara invested $5 million for a 6.6% ownership in ChemoMouthpiece. Sanara has drawn $15.5 million on its term loan with CRG Servicing, LLC and will fund this investment as part of that draw.
SI Technologies will have the option to purchase the U.S. business of ChemoMouthpiece, including all U.S. intellectual property related to the product. The purchase option will expire on Jan. 31, 2029.
<h2>More on the News</h2>
Oral mucositis causes painful mouth ulcers, which are a common complication of chemotherapy and radiation. The oral cryotherapy device is expected to reduce material costs for oncology treatment centers, improve patient quality of life and allow for continued treatment of cancer therapy for patients. ChemoMouthpiece is planning to publish studies in the future to reinforce the efficacy of the device.
Pickwick Capital Partners, LLC, served as the exclusive advisor to ChemoMouthpiece on this transaction.
<h2>Recent Development by Sanara</h2>
Earlier this year, Sanara signed an exclusive license agreement with Tufts University (Tufts) to develop and commercialize patented technology covering 18 unique collagen peptides.&nbsp;
Although Sanara has established itself as a leader in bioactive collagen peptides with CellerateRX&nbsp;Surgical Powder, the company expects to expand the CellerateRX product line and develop new bioactive collagen peptide-based applications. The recently licensed technology from Tufts helped the company to expand its offering of collagen products.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/aa/77485.jpg?v=996577913" />
Image Source: Zacks Investment Research
<h2>Industry Prospects Favor Sanara</h2>
Per a Global Market Insights report, the oral mucositis treatment market was valued at $1.6 billion in 2023 and is expected to witness a CAGR of 7.1% from 2024 to 2032.&nbsp;
Market growth can be attributed to the ongoing advancements in cancer therapy and the increasing prevalence of cancer. Moreover, the rising geriatric population, along with the growing demand for targeted therapies, helps the market surge.
<h2>Price Performance by Sanara</h2>
In the past year, shares of SMTI have lost 5.8% against the industry&#39;s 18.4% growth.
<h2>SMTI&#39;s Zacks Rank and Key Picks</h2>
Sanara currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Intuitive Surgical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), TransMedics Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) and Boston Scientific. While Intuitive Surgical and TransMedics currently sport a Zacks Rank #1 (Strong Buy) each, Boston Scientificcarries a Zacks Rank #2 (Buy).
Intuitive Surgical&#39;s shares have surged 62.2% in the past year. Estimates for the company&#39;s earnings have moved north 5.1% to $1.65 per share for 2024 in the past 30 days.
ISRG&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.
Estimates for TransMedics&#39; 2024 EPS have moved up 125% to 27 cents in the past 30 days. Shares of the company have soared 143.8% in the past year compared with the industry&#39;s 15.8% growth.
TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.
Estimates for Boston Scientific&#39;s 2024 EPS have increased 1.7% to $2.40 in the past 30 days. In the past year, shares of BSX have risen 55.9% compared with the industry&#39;s 18.3% growth.
In the last reported quarter, BSX delivered an earnings surprise of 6.90%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.18%.
<a href="https://www.zacks.com/stock/news/2335233/sanara-stock-gains-from-new-us-distribution-deal-with-chemomouthpiece?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2335233">To read this article on Zacks.com click here.</a>

Biotech

Earnings

Earnings Beats

Large Cap

Mid Cap

Health Care

Small Cap

Markets

General

ISRG

SMTI

TMDX

Sanara Stock Gains From New US Distribution Deal With ChemoMouthPiece

Goldman Sachs analyst Caitlin Burrows maintains Kimco Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIM#NYSE">KIM</a>) with a Neutral and raises the price target from $20 to $22.5.

Goldman Sachs Maintains Neutral on Kimco Realty, Raises Price Target to $22.5

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) with a Buy and maintains $5.75 price target.

Reiteration

VYNE

HC Wainwright & Co. Reiterates Buy on VYNE Therapeutics, Maintains $5.75 Price Target

Thursday, GSK plc (LSE/NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) announced headline results of a phase 2 trial for its mRNA seasonal <a href="https://www.benzinga.com/topic/influenza">influenza vaccine program</a>.
The <a href="https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-headline-data-from-phase-ii-seasonal-influenza-mrna-vaccine-programme/" target="_blank" rel="noreferrer noopener">trial</a> studied a range of mRNA formulations in older and younger adults to evaluate vaccine candidates that could improve immune responses against influenza A and B strains, compared to the current standard of care.
The data demonstrated positive immune responses against influenza A and B strains compared to the current standard of care, meeting all predefined success criteria in the tested age groups of older and younger adults.
Also Read: <a href="https://www.benzinga.com/general/biotech/24/09/40817991/gsk-halts-herpes-simplex-virus-vaccine-development-clears-path-for-other-contenders-like-moderna-" target="_blank" rel="noreferrer noopener">GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech</a>.
Interim data suggest the vaccine candidates have an acceptable safety and reactogenicity profile for all mRNA formulations tested.
These results build on the previous phase 2 trial and confirm the mRNA platform elicits strong overall antibody titres with an acceptable safety profile.
With these results, the GSK mRNA seasonal influenza vaccine program will progress into late-stage clinical development.
Vaccine candidate based on CureVac N.V.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) proprietary second-generation mRNA backbone
The Phase 2 study was <a target="_blank" href="https://www.curevac.com/en/curevac-partner-gsk-announces-positive-phase-2-data-from-seasonal-influenza-mrna-vaccine-program/" rel="noreferrer noopener">initiated</a> following interim data reported in April from the Phase 2 part of the ongoing combined Phase 1/2 study in seasonal influenza.
In July, GSK and&nbsp;CureVac restructured their existing collaboration into a new licensing agreement, allowing the companies to prioritize investment and focus on their respective mRNA <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39615546/gsk-buys-full-rights-to-investigational-covid-19-and-influenza-vaccines-from-curevac-for-around-1" rel="noreferrer noopener">development activities</a>.
Since 2020, GSK and CureVac have&nbsp;<a target="_blank" href="https://www.curevac.com/en/gsk-and-curevac-to-restructure-collaboration-into-new-licensing-agreement/" rel="noreferrer noopener">worked</a>&nbsp;together to develop mRNA vaccines for infectious diseases.
Price Action: GSK stock is down 0.91% at $43.37, and CVAC stock is down 1.98% at $2.97 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/24/09/40834852/nvidia-ai-chips-headed-to-saudi-arabia-us-reassesses-export-ban" target="_blank" rel="noreferrer noopener">Nvidia AI Chips Headed to Saudi Arabia, US Reassesses Export Ban</a></li>
</ul>

CVAC

GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza mRNA Vaccine

Fulcrum Therapeutics Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) stock is trading lower on Thursday after the company released data from the Phase 3 REACH trial evaluating losmapimod in patients with Facioscapulohumeral <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40828987/fulcrum-therapeutics-announces-topline-results-from-phase-3-reach-clinical-trial-of-losmapimod-in-" rel="noreferrer noopener">Muscular Dystrophy (FSHD)</a>.
The study did not achieve its primary endpoint of change from baseline in relative surface area&nbsp;(RSA) with losmapimod compared to placebo.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40779934/fulcrum-therapeutics-upgraded-bofa-debates-pivotal-study-success-for-losmapimod-in-" rel="noreferrer noopener">Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease</a>.
In addition, secondary endpoints did not achieve nominal statistical significance. Losmapimod&#8217;s safety and tolerability profile was consistent with previously reported studies.
The company will complete a full evaluation of the data it received this week and plans to share the results at an upcoming medical meeting.
<ul>
<li>Participants receiving losmapimod demonstrated a 0.013 (±0.007) improvement in RSA at week 48 compared to placebo patients, who showed a 0.010 improvement in RWS (p-value = 0.75).</li>
<li>RSA measures reachable workspace (RWS), an outcome measure used to track disease progression in neuromuscular disorders that affect the upper extremities.</li>
<li>Participants receiving losmapimod demonstrated an increase of 0.42% in Muscle Fat Infiltration (a measurement indicating the quality of the muscle) at week 48 compared to participants receiving placebo, who showed an increase of 0.576% (p-value = 0.16).</li>
<li>Participants receiving losmapimod demonstrated a 9.63% improvement in abductor strength at week 48 compared to a 2.24% improvement in the placebo arm of the study (p-value = 0.51).</li>
</ul>
The rate of treatment-related adverse events was similar in the two treatment arms, and there were no treatment-related serious adverse events in participants receiving losmapimod.
&#8220;We are deeply disappointed that the REACH trial did not replicate the clinical results observed in the Phase 2 ReDUX4 trial,&#8221; said Alex Sapir, Fulcrum&#8217;s president and CEO. &#8220;In light of these results, we plan to suspend the losmapimod program in FSHD.&#8221;
As previously disclosed, Fulcrum had approximately $273.8 million in cash, cash equivalents, and marketable securities as of June 30, 2024.
Fulcrum intends to use these resources to advance pociredir for sickle cell disease, novel therapeutic agents for Diamond-Blackfan Anemia, and early discovery programs.
Price Action: FULC stock is down 59.30% at $3.60 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40832349/mastercard-expands-cyber-defense-with-2-65b-deal-for-recorded-future-whats-on-the-cards" target="_blank" rel="noreferrer noopener">Mastercard Expands Cyber Defense With $2.65B Deal For Recorded Future &#8211; What&#8217;s On The Cards?</a></li>
</ul>

Movers

FULC

Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial

Goldman Sachs analyst Alexander Blostein maintains Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) with a Buy and raises the price target from $41 to $47.

Goldman Sachs Maintains Buy on Brookfield Asset Mgmt, Raises Price Target to $47

Sirius XM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>) has outperformed the market over the past 10 years by 11.09% on an annualized basis producing an average annual return of 21.82%. Currently, Sirius XM Holdings has a market capitalization of $9.24 billion. 
Buying $1000 In SIRI: If an investor had bought $1000 of SIRI stock 10 years ago, it would be worth $7,248.27 today based on a price of $28.28 for SIRI at the time of writing.
<h3>Sirius XM Holdings's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726155029_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SIRI

Here's How Much $1000 Invested In Sirius XM Holdings 10 Years Ago Would Be Worth Today

ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) has outperformed the market over the past 15 years by 10.84% on an annualized basis producing an average annual return of 22.48%. Currently, ASML Holding has a market capitalization of $313.81 billion. 
Buying $100 In ASML: If an investor had bought $100 of ASML stock 15 years ago, it would be worth $2,114.98 today based on a price of $797.65 for ASML at the time of writing.
<h3>ASML Holding's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726155024_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASML

Here's How Much $100 Invested In ASML Holding 15 Years Ago Would Be Worth Today

Heartland Financial USA's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTLF#NYSE">HTLF</a>) short percent of float has risen 42.41% since its last report. The company recently reported that it has 986 thousand shares sold short, which is 2.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.1 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Heartland Financial USA Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726155021_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Heartland Financial USA has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Heartland Financial USA's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Heartland Financial USA's peer group average for short interest as a percentage of float is 5.30%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

HTLF

How Is The Market Feeling About Heartland Financial USA?

Zoom Video Comms's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NYSE">ZM</a>) short percent of float has risen 36.27% since its last report. The company recently reported that it has 10.51 million shares sold short, which is 4.02% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.67 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Zoom Video Comms Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726155016_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Zoom Video Comms has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Zoom Video Comms's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Zoom Video Comms's peer group average for short interest as a percentage of float is 3.15%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Zoom Video Comms's Recent Short Interest

Star Bulk Carriers's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBLK#NYSE">SBLK</a>) short percent of float has risen 8.65% since its last report. The company recently reported that it has 2.55 million shares sold short, which is 2.26% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.44 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Star Bulk Carriers Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726155010_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Star Bulk Carriers has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Star Bulk Carriers's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Star Bulk Carriers's peer group average for short interest as a percentage of float is 3.11%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SBLK

How Is The Market Feeling About Star Bulk Carriers?

<a href="https://www.barrons.com/articles/this-reit-with-a-15-yield-may-have-a-dividend-problem-heres-why-69c674e2" title="https://www.barrons.com/articles/this-reit-with-a-15-yield-may-have-a-dividend-problem-heres-why-69c674e2">https://www.barrons.com/articles/this-reit-with-a-15-yield-may-have-a-dividend-problem-heres-why-69c674e2</a>
Kamala Harris and Donald Trump don't agree on much, except <a href="https://www.barrons.com/articles/us-steel-stock-price-biden-merger-3315dd16?mod=article_inline">stopping</a> Japan's <a href="https://www.barrons.com/market-data/stocks/5401?countrycode=jp&amp;mod=article_chiclet">Nippon Steel</a>'s proposed $15 billion acquisition of <a href="https://www.barrons.com/market-data/stocks/x?mod=article_chiclet">U.S. Steel</a>. Joe Biden's White House has signaled that it will nix <a href="https://www.barrons.com/articles/u-s-steel-stock-buy-sell-bb980316?mod=article_inline">the deal</a> as a supposed threat to U.S. national security.

'U.S. Steel Deal Looks Dead. Japan Won't Hold A Grudge' - Barron's

Oppenheimer analyst Leland Gershell reiterates SAB Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABS#NASDAQ">SABS</a>) with a Outperform and maintains $12 price target.

SABS

Oppenheimer Reiterates Outperform on SAB Biotherapeutics, Maintains $12 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Sernova (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SVA#TSX">SVA</a>) with a Buy and maintains C$6 price target.

TSX:SVA

HC Wainwright & Co. Reiterates Buy on Sernova, Maintains C$6 Price Target

UBS analyst Timothy Arcuri maintains Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) with a Buy and lowers the price target from $1250 to $1150.

LRCX

UBS Maintains Buy on Lam Research, Lowers Price Target to $1150

Today, the U.S. Food and Drug Administration authorized the first over-the-counter (OTC) hearing aid software device, Hearing Aid Feature, intended to be used with compatible versions of the Apple AirPods Pro headphones. Once installed and customized to the user's hearing needs, the Hearing Aid Feature enables compatible versions of the AirPods Pro to serve as an OTC hearing aid, intended to amplify sounds for individuals 18 years or older with perceived mild to moderate hearing impairment.
"Hearing loss is a significant public health issue impacting millions of Americans," said Michelle Tarver, M.D., Ph.D., acting director of the FDA's Center for Devices and Radiological Health.&nbsp;"Today's marketing authorization of an over-the-counter hearing aid software on a widely used consumer audio product is another step that advances the availability, accessibility and acceptability of hearing support for adults with perceived mild to moderate hearing loss."
More than 30 million American adults report some degree of hearing loss.&nbsp;Hearing loss can be caused by aging, exposure to loud noises, certain medical conditions, and other factors. Hearing loss can have a negative effect on communication, relationships, school or work performance and emotional well-being. Using hearing aids has been <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4253485-1&amp;h=3658607187&amp;u=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2022%2F08%2F17%2F2022-17230%2Fmedical-devices-ear-nose-and-throat-devices-establishing-over-the-counter-hearing-aids%23p-666&amp;a=linked">linked</a> to reductions in the frequency or severity of cognitive decline, depression and other health problems in older adults.&nbsp;
The <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4253485-1&amp;h=229452156&amp;u=https%3A%2F%2Fweb.archive.org%2Fweb%2F20221028042729%2Fhttps%3A%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-finalizes-historic-rule-enabling-access-over-counter-hearing-aids-millions-americans&amp;a=FDA%27s+OTC+hearing+aid+regulations">FDA's OTC hearing aid regulations</a>&nbsp;established in October 2022 represented a significant step toward helping ensure that adults with mild to moderate hearing loss have improved access to more safe and effective product options. The rule enabled consumers with perceived mild to moderate hearing impairment to purchase hearing aids directly from stores or online retailers without the need for a medical exam, prescription or seeing an audiologist. Today's authorization exemplifies the FDA's continued commitment to provide safe and effective solutions for those with hearing loss, while also fostering innovation and convenience.
The Hearing Aid Feature (HAF) is a software-only mobile medical application that is intended to be used with compatible versions of the AirPods Pro. The HAF utilizes a self-fitting strategy, and users may adjust it to meet their hearing needs without the assistance of a hearing professional. The HAF is set up using an iOS device (e.g., iPhone, iPad), and the user's hearing levels are accessed from the iOS HealthKit to customize the HAF. Users can refine the volume, tone and balance settings after setting up the HAF.
The HAF was evaluated in a clinical study with 118 subjects with perceived mild to moderate hearing loss, at multiple U.S. sites. The results demonstrated that subjects who used the HAF self-fitting strategy achieved similar perceived benefit as subjects who received professional fitting of the same device. Results also showed comparable performance for tests measuring levels of amplification in the ear canal, as well as a measure of speech understanding in noise. No adverse events related to the device were observed in this study.
This application was reviewed under the FDA's&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4253485-1&amp;h=2478959766&amp;u=https%3A%2F%2Fwww.fda.gov%2Fmedical-devices%2Fpremarket-submissions-selecting-and-preparing-correct-submission%2Fde-novo-classification-request&amp;a=De+Novo+premarket+review+pathway">De Novo premarket review pathway</a>, a regulatory pathway for some low- to moderate-risk devices that are novel and for which there is no prior legally marketed device.
As part of the Center for Devices and Radiological Health's strategic priority to advance health equity, the Center will continue to support innovation that expands access to important technologies and brings health care directly to patients.
The FDA granted marketing authorization&nbsp;of the Hearing Aid Feature to Apple Inc.

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Arcandor

News

Latest news for Arcandor (OTC:ACAGF) Stock